View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 30, 2018	Apr. 13, 2018
Document And Entity Information [Abstract]
Document type	10-Q
Amendment flag	false
Document period end date	Mar. 30, 2018
Document fiscal year focus	2018
Document fiscal period focus	Q1
Trading symbol	dhr
Entity registrant name	DANAHER CORP /DE/
Entity central index key	0000313616
Current fiscal year end date	--12-31
Entity filer category	Large Accelerated Filer
Entity common stock, shares outstanding		698,572,727

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 30, 2018	Dec. 31, 2017
Current assets:
Cash and equivalents	$ 1,045.7	$ 630.3
Trade accounts receivable, net	3,270.7	3,521.8
Inventories:
Finished goods	1,059.3	982.5
Work in process	302.0	309.7
Raw materials	587.8	548.6
Total inventories	1,949.1	1,840.8
Prepaid expenses and other current assets	809.6	857.1
Total current assets	7,075.1	6,850.0
Property, plant and equipment, net of accumulated depreciation of $2,652.0 and $2,519.4, respectively	2,475.9	2,454.6
Other long-term assets	575.3	538.3
Goodwill	25,437.9	25,138.6
Other intangible assets, net	11,581.0	11,667.1
Total assets	47,145.2	46,648.6
Current liabilities:
Notes payable and current portion of long-term debt	98.7	194.7
Trade accounts payable	1,579.0	1,509.9
Accrued expenses and other liabilities	2,765.2	3,087.7
Total current liabilities	4,442.9	4,792.3
Other long-term liabilities	5,089.8	5,161.1
Long-term debt	10,410.7	10,327.4
Stockholders’ equity:
Common stock - $0.01 par value, 2.0 billion shares authorized; 814.8 and 812.5 issued; 698.5 and 696.6 outstanding, respectively	8.1	8.1
Additional paid-in capital	5,611.1	5,538.2
Retained earnings	23,415.4	22,806.1
Accumulated other comprehensive income (loss)	(1,844.7)	(1,994.2)
Total Danaher stockholders’ equity	27,189.9	26,358.2
Noncontrolling interests	11.9	9.6
Total stockholders’ equity	27,201.8	26,367.8
Total liabilities and stockholders’ equity	$ 47,145.2	$ 46,648.6

Consolidated Condensed Balance Sheets Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Mar. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Property, plant and equipment, net of accumulated depreciation	$ 2,652.0	$ 2,519.4
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000.0	2,000.0
Common stock, shares issued	814.8	812.5
Common stock, shares outstanding	698.5	696.6

Consolidated Condensed Statements Of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Income Statement [Abstract]
Sales	$ 4,695.4	$ 4,205.7
Cost of sales	(2,051.8)	(1,871.4)
Gross profit	2,643.6	2,334.3
Operating costs:
Selling, general and administrative expenses	(1,601.9)	(1,449.9)
Research and development expenses	(298.7)	(267.4)
Operating profit	743.0	617.0
Nonoperating income (expense):
Other income, net	7.8	6.9
Interest expense	(39.1)	(40.3)
Interest income	1.4	1.6
Earnings from continuing operations before income taxes	713.1	585.2
Income taxes	(146.5)	(101.4)
Net earnings from continuing operations	566.6	483.8
Earnings from discontinued operations, net of income taxes	0.0	22.3
Net earnings	$ 566.6	$ 506.1
Net earnings per share:
Net earnings per share from continuing operations, basic (in dollars per share)	$ 0.81	$ 0.70
Net earnings per share from continuing operations, diluted (in dollars per share)	0.80	0.69
Net earnings per share from discontinued operations, basic (in dollars per share)	0.00	0.03
Net earnings per share from discontinued operations, diluted (in dollars per share)	0.00	0.03
Net earnings per share, basic (dollars per share)	0.81	0.73
Net earnings per share, diluted (dollars per share)	$ 0.80	$ 0.72
Average common stock and common equivalent shares outstanding:
Basic (shares)	698.6	694.3
Diluted (shares)	709.5	705.7

Consolidated Condensed Statements Of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Statement of Comprehensive Income [Abstract]
Net earnings	$ 566.6	$ 506.1
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	294.1	304.3
Pension and postretirement plan benefit adjustments	7.1	4.9
Unrealized (loss) gain on available-for-sale securities adjustments	(0.5)	7.3
Total other comprehensive income (loss), net of income taxes	300.7	316.5
Comprehensive income	$ 867.3	$ 822.6

Consolidated Condensed Statement Of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standards, January 1, 2018, amount				$ 154.5	$ (151.2)
Adjusted balance, January 1, 2018, amount		$ 8.1	$ 5,538.2	22,960.6	(2,145.4)	$ 9.6
Balance, December 31, 2017, shares at Dec. 31, 2017		812.5
Balance, December 31, 2017, amount at Dec. 31, 2017	$ 26,367.8	$ 8.1	5,538.2	22,806.1	(1,994.2)	9.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings for the period	566.6			566.6
Other comprehensive income	300.7				300.7
Dividends declared				(111.8)
Common stock-based award activity, shares		1.9
Common stock-based award activity, amount		$ 0.0	61.0
Common stock issued in connection with LYONs’ conversions, including tax benefit of $3.1, shares		0.4
Common stock issued in connection with LYONs’ conversions, including tax benefit of $3.1, amount		$ 0.0	11.9
Change in noncontrolling interests						2.3
Balance, March 30, 2018, shares at Mar. 30, 2018		814.8
Balance, March 30, 2018, amount at Mar. 30, 2018	$ 27,201.8	$ 8.1	$ 5,611.1	$ 23,415.4	$ (1,844.7)	$ 11.9

Consolidated Condensed Statement Of Stockholders' Equity Consolidated Condensed Statement Of Stockholders' Equity (Parenthetical) $ in Millions	3 Months Ended
	Mar. 30, 2018 USD ($)
Statement of Stockholders' Equity [Abstract]
Debt conversion, converted instrument, tax benefit	$ 3.1

Consolidated Condensed Statements Of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net earnings	$ 566.6	$ 506.1
Less: earnings from discontinued operations, net of income taxes	0.0	(22.3)
Net earnings from continuing operations	566.6	483.8
Noncash items:
Depreciation	148.5	139.5
Amortization	172.3	166.1
Stock-based compensation expense	33.3	33.6
Change in trade accounts receivable, net	219.0	168.3
Change in inventories	(128.9)	(56.9)
Change in trade accounts payable	51.4	(90.9)
Change in prepaid expenses and other assets	125.0	59.4
Change in accrued expenses and other liabilities	(358.3)	(342.7)
Net operating cash provided by continuing operations	828.9	560.2
Cash flows from investing activities:
Payments for additions to property, plant and equipment	(137.9)	(158.6)
Proceeds from sales of property, plant and equipment	0.4	0.7
Proceeds from sale of investments	21.9	0.0
All other investing activities	(7.1)	(5.8)
Net operating cash used in investing activities	(122.7)	(163.7)
Cash flows from financing activities:
Proceeds from the issuance of common stock	23.2	20.5
Payment of dividends	(97.5)	(86.6)
Payment for purchase of noncontrolling interests	0.0	(64.4)
Net repayments of borrowings (maturities of 90 days or less)	(236.6)	(434.9)
All other financing activities	(10.8)	(25.3)
Net operating cash used in financing activities	(321.7)	(590.7)
Effect of exchange rate changes on cash and equivalents	30.9	34.4
Net change in cash and equivalents	415.4	(159.8)
Beginning balance of cash and equivalents	630.3	963.7
Ending balance of cash and equivalents	1,045.7	803.9
Supplemental disclosures:
Cash interest payments	47.7	48.2
Cash income tax payments	$ 133.5	$ 142.3

General

3 Months Ended

Mar. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

General

GENERAL

The consolidated condensed financial statements included herein have been prepared by Danaher Corporation (“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its consolidated subsidiaries or the consolidated subsidiaries of Danaher Corporation, as the context requires. Unless otherwise indicated, all amounts in this quarterly report refer to continuing operations. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated Condensed Financial Statements included herein should be read in conjunction with the financial statements as of and for the year ended December 31, 2017 and the Notes thereto included in the Company’s 2017 Annual Report on Form 10-K filed on February 21, 2018.

In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of March 30, 2018 and December 31, 2017, its results of operations for the three-month periods ended March 30, 2018 and March 31, 2017 and its cash flows for each of the three-month periods then ended. Reclassifications of certain prior year amounts have been made to conform to the current year presentation.

Accounting Standards Recently Adopted

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) which supersedes nearly all existing revenue recognition guidance. Subsequent to the issuance of Topic 606, the FASB clarified the guidance through several Accounting Standard Updates; hereinafter the collection of revenue guidance is referred to as “ASC 606”. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

On January 1, 2018, the Company adopted ASC 606 using the modified retrospective method for all contracts. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with the Company’s historic accounting under Topic 605, Revenue Recognition.

The Company recorded a net increase to beginning retained earnings of $3 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606. The impact to beginning retained earnings was primarily driven by the capitalization of certain costs to obtain a contract, primarily sales-related commissions, partially offset by the deferral of revenue for unfulfilled performance obligations. The adoption of ASC 606 did not have a significant impact on the Company’s Consolidated Condensed Financial Statements as of and for the three-month period ended March 30, 2018 and, as a result, comparisons of revenues and operating profit performance between periods are not affected by the adoption of this ASU. Refer to Note 2 for additional disclosures required by ASC 606.

The Company derives revenues primarily from the sale of Life Sciences, Diagnostics, Dental and Environmental & Applied Solutions products and services. Revenue is recognized when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. For equipment, consumables, spare parts and most software licenses sold by the Company, control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment, legal title must have passed to the customer, the customer must have the significant risks and rewards of ownership, and where acceptance is not a formality, the customer must have accepted the product or service. The Company’s principal terms of sale are FOB Shipping Point, or equivalent, and, as such, the Company primarily transfers control and records revenue for product sales upon shipment. Sales arrangements with delivery terms that are not FOB Shipping Point are not recognized upon shipment and the transfer of control for revenue recognition is evaluated based on the associated shipping terms and customer obligations. If a performance obligation to the customer with respect to a sales transaction remains to be fulfilled following shipment (typically installation or acceptance by the customer), revenue recognition for that performance obligation is deferred until such commitments have been fulfilled. Returns for products sold are estimated and recorded as a reduction of revenue at the time of sale. Customer allowances and rebates, consisting primarily of volume discounts and other short-term incentive programs, are recorded as a reduction of revenue at the time of sale because these allowances reflect a reduction in the transaction price. Product returns, customer allowances and rebates are estimated based on historical experience and known trends. For extended warranty, service, post contract support (“PCS”), software-as-a-service (“SaaS”) and other long-term contracts, control transfers to the customer over the term of the arrangement. Revenue for extended warranty, service, PCS, SaaS and certain software licenses is recognized based upon the period of time elapsed under the arrangement. Revenue for other long-term contracts is generally recognized based upon the cost-to-cost measure of progress, provided that the Company meets the criteria associated with transferring control of the good or service over time.

Certain of the Company’s revenues relate to operating-type lease (“OTL”) arrangements. Leases are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Instrument lease revenue for OTL agreements is recognized on a straight-line basis over the life of the lease, and the costs of customer-leased instruments are recorded within property, plant and equipment in the accompanying Consolidated Balance Sheets and depreciated over the instrument’s estimated useful life. The depreciation expense is reflected in cost of sales in the accompanying Consolidated Statements of Earnings. The OTLs are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of consumables or tests throughout the contract term. Certain of the Company’s lease contracts are customized for larger customers and often result in complex terms and conditions that typically require significant judgment in applying the criteria used to evaluate whether the arrangement should be considered an OTL or a sales-type lease (“STL”). A sales-type lease would result in earlier recognition of instrument revenue as compared to an OTL.

For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts’ inception. The Company does not adjust transaction price for the effects of a significant financing component when the period between the transfer of the promised good or service to the customer and payment for that good or service by the customer is expected to be one year or less. This allocation approach also applies to contracts for which a portion of the contract relates to a lease component.

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU amends guidance on the classification and measurement of financial instruments, including significant revisions in accounting related to the classification and measurement of investments in equity securities and presentation of certain fair value changes for financial liabilities when the fair value option is elected. The ASU requires equity securities to be measured at fair value with changes in fair value recognized through net earnings and amends certain disclosure requirements associated with the fair value of financial instruments. In the period of adoption, the Company is required to reclassify the unrealized gains/losses on equity securities within accumulated other comprehensive income (loss) to retained earnings. In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10), which clarified certain aspects of the previously issued ASU. The ASU was adopted by the Company on January 1, 2018 and did not have a material effect on the Company’s Consolidated Financial Statements.

In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which requires employers to disaggregate the service cost component from other components of net periodic benefit costs and to disclose the amounts of net periodic benefit costs that are included in each income statement line item. The standard requires employers to report the service cost component in the same line item as other compensation costs and to report the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. The income statement guidance requires application on a retrospective basis. The ASU was adopted by the Company on January 1, 2018 and as a result operating profit decreased and other income, net increased by $6.9 million for the three-month period March 31, 2017. Refer to Note 8 for further information on the implementation of this ASU.

The Company measures its pension and postretirement plans’ assets and its obligations that determine the respective plan’s funded status as of the end of the Company’s fiscal year, and recognizes an asset for a plan’s overfunded status or a liability for a plan’s underfunded status in its balance sheet. Changes in the funded status of the plans are recognized in the year in which the changes occur and reported in other comprehensive income (loss). The service cost component of net periodic pension cost is included in cost of sales and selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings and the other components of net periodic pension cost are included in nonoperating income (expense).

In February 2018, the FASB issued ASU No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to address a specific consequence of the Tax Cuts and Jobs Act (“TCJA”) by allowing a reclassification from accumulated other comprehensive income (loss) to retained earnings for stranded tax effects resulting from the TCJA’s reduction of the U.S. federal corporate income tax rate. The standard is effective for all entities for annual periods beginning after December 15, 2018, with early adoption permitted, and is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company early adopted this ASU on January 1, 2018 and as a result recorded a net increase to beginning retained earnings and decrease to accumulated other comprehensive income (loss) of $151 million to reclassify the income tax effects of the TCJA on the Company’s U.S. pension plans, available-for-sale debt securities and certain foreign currency losses. The ASU also requires the Company to disclose its policy on accounting for income tax effects in accumulated other comprehensive income (loss). In general, the Company applies the individual item approach with respect to available-for-sale debt securities and the portfolio approach with respect to pension, postretirement benefit plan obligations and currency translation matters.

In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the TCJA. The Company recognized the estimated income tax effects of the TCJA in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 (“SAB No. 118”). Refer to Note 9 for further information regarding the provisional amounts recorded by the Company as of December 31, 2017.

Except for the above accounting policy for revenue recognition that was updated as a result of adopting ASC 606 and the policy for pension and postretirement benefit plans that was updated as a result of adopting ASU 2017-07, there have been no changes to the Company’s significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2017 that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes.

Accounting Standards Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Currently, the Company believes that the most notable impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use asset and a lease liability for all leases with terms greater than 12 months. The standard also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. The ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. In September 2017 and January 2018, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), and ASU No. 2018-01, Leases (Topic 842), Land Easement Practical Expedient for Transition to Topic 842, which provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. The Company is in the early stages of implementation and currently believes that the most notable impact to its financial statements upon the adoption of this ASU will be the recognition of a material right-of-use asset and a lease liability for its real estate and equipment leases.

Accumulated Other Comprehensive Income (Loss)—The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions). Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries.



	Foreign Currency Translation Adjustments			Pension & Postretirement Plan Benefit Adjustments				Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments			Total
For the Three-Month Period Ended March 30, 2018:
Balance, December 31, 2017	$	(1,422.1	)	$	(571.2	)		$	(0.9	)	$	(1,994.2	)
Adoption of accounting standards	(43.8		)	(107.2		)		(0.2		)	(151.2		)
Balance, January 1, 2018	(1,465.9		)	(678.4		)		(1.1		)	(2,145.4		)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	294.1			—				(0.8		)	293.3
Income tax impact	—			—				0.3			0.3
Other comprehensive income (loss) before reclassifications, net of income taxes	294.1			—				(0.5		)	293.6
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			9.3			(a)	—			9.3
Income tax impact	—			(2.2		)		—			(2.2		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			7.1				—			7.1
Net current period other comprehensive income (loss), net of income taxes	294.1			7.1				(0.5		)	300.7
Balance, March 30, 2018	$	(1,171.8	)	$	(671.3	)		$	(1.6	)	$	(1,844.7	)
For the Three-Month Period Ended March 31, 2017:
Balance, December 31, 2016	$	(2,398.2	)	$	(642.2	)		$	18.7		$	(3,021.7	)
Other comprehensive income (loss) before reclassifications:
Increase	304.3			—				11.7			316.0
Income tax impact	—			—				(4.4		)	(4.4		)
Other comprehensive income (loss) before reclassifications, net of income taxes	304.3			—				7.3			311.6
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			7.6			(a)	—			7.6
Income tax impact	—			(2.7		)		—			(2.7		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			4.9				—			4.9
Net current period other comprehensive income (loss), net of income taxes	304.3			4.9				7.3			316.5
Balance, March 31, 2017	$	(2,093.9	)	$	(637.3	)		$	26.0		$	(2,705.2	)

^(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 8 for additional details.

Revenue (Notes)

3 Months Ended

Mar. 30, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer

REVENUE

The following table presents the Company’s revenues disaggregated by geographical region and revenue type for the three-month period ended March 30, 2018 ($ in millions). Sales taxes and other usage-based taxes are excluded from revenues. The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which includes Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not high-growth markets.



	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	480.4	$	607.4	$	291.3	$	418.3	$	1,797.4
Western Europe	449.9		310.4		175.6		264.8		1,200.7
Other developed markets	144.9		92.2		43.9		31.6		312.6
High-growth markets	400.8		509.7		161.8		312.4		1,384.7
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

Revenue type:
Recurring	$	970.4	$	1,308.5	$	488.0	$	557.0	$	3,323.9
Nonrecurring	505.6		211.2		184.6		470.1		1,371.5
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

The Company sells equipment to customers as well as consumables, spare parts, software licenses and services that customers purchase on a recurring basis. Consumables are typically critical to the use of the equipment and are used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, filters used in filtration, separation and purification processes, and cartridges for marking and coding equipment. Additionally, some of the Company’s consumables are used on a standalone basis, such as dental implants and water treatment solutions. The Company separates its goods and services between those sold on a recurring basis and those sold on a nonrecurring basis. Recurring revenue includes revenue from consumables, services, spare parts, software licenses recognized over time, SaaS, sales-and-usage based royalties and OTLs. Nonrecurring revenue includes sales from equipment, software licenses recognized at a point in time and STLs. OTLs and STLs are included in the above revenue amounts. For the three-month period ended March 30, 2018, revenue accounted for under Topic 840, Leases was $97 million.

Remaining Performance Obligations

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include noncancelable purchase orders, the non-lease portion of minimum purchase commitments under long-term consumable supply arrangements, extended warranty, service and PCS contracts, SaaS and other long-term contracts. Remaining performance obligations do not include revenue from contracts with customers with an original term of one year or less, revenue from long-term consumable supply arrangements with no minimum purchase requirements or revenue expected from purchases made in excess of the minimum purchase requirements or revenue from equipment leased to customers. While the remaining performance obligation disclosure is similar in concept to backlog, the definition of remaining performance obligations excludes leases and contracts that provide the customer with the right to cancel or terminate for convenience with no substantial penalty, even if historical experience indicates the likelihood of cancellation or termination is remote. Additionally, the Company has elected to exclude contracts with customers with an original term of one year or less from remaining performance obligations while these contracts are included within backlog.

As of March 30, 2018, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $1.7 billion. The Company expects to recognize revenue on approximately 72% of the remaining performance obligations over the next 24 months, 44% recognized in the first 12 months and 28% recognized over the subsequent 12 months, and the remainder recognized thereafter.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Consolidated Condensed Balance Sheets. In addition, the Company defers certain costs incurred to obtain a contract (contract costs).

Contract assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Condensed Balance Sheet. The balance of contract assets as of March 30, 2018 and at the date of adoption of ASC 606 were $94 million and $114 million, respectively.

Contract liabilities—The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Condensed Balance Sheet based on the timing of when the Company expects to recognize revenue. As of March 30, 2018 and at the date of adoption of ASC 606, contract liabilities were $801 million and $783 million, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheet. The increase in the contract liability balance during the three-month period ended March 30, 2018 is primarily as a result of cash payments received in advance of satisfying performance obligations and foreign currency exchange, offset by $265 million of revenue recognized during the period that was included in the contract liability balance at the date of adoption.

Contract costs—The Company capitalizes certain direct incremental costs incurred to obtain a contract, typically sales-related commissions, where the recognition period for the related revenue is greater than one year. These costs are amortized over the contract term or a longer period, generally the expected life of the customer relationship if renewals are expected and the renewal commission is not commensurate with the initial commission. Contract costs are classified as current or long-term other assets in the Consolidated Condensed Balance Sheet based on the timing of when the Company expects to recognize the expense and are generally amortized into earnings on a straight-line basis (which is consistent with the transfer of control for the related goods or services). Management assesses these costs for impairment at least quarterly and as “triggering” events occur that indicate it is more likely than not that an impairment exists. The balance of contract costs as of March 30, 2018 and at the date of adoption were not significant. Amortization expense for the three-month period ended March 30, 2018, was also not significant. The costs to obtain a contract where the amortization period for the related asset is one year or less are expensed as incurred and recorded within selling, general and administrative expenses in the accompanying Consolidated Condensed Statement of Earnings.

Contract assets, liabilities and costs are reported on the accompanying Consolidated Condensed Balance Sheet on a contract-by-contract basis.

Acquisitions

3 Months Ended

Mar. 30, 2018

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

For a description of the Company’s acquisition activity for the year ended December 31, 2017 reference is made to the financial statements as of and for the year ended December 31, 2017 and Note 2 thereto included in the Company’s 2017 Annual Report.

The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s financial statements. This goodwill arises because the purchase prices for these businesses reflect a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses, anticipated opportunities for synergies from the elimination of redundant facilities and staffing and use of each party’s respective, existing commercial infrastructure to cost-effectively expand sales of the other party’s products and services, and the complementary strategic fit and resulting synergies these businesses bring to existing operations.

The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through other sources. In the months after closing, as the Company obtains additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. The Company is continuing to evaluate certain pre-acquisition contingencies associated with certain of its 2017 acquisitions and is also in the process of obtaining valuations of certain property, plant and equipment, acquired intangible assets and certain acquisition-related liabilities in connection with these acquisitions. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required.

In April 2018, the Company acquired Integrated DNA Technologies, Inc. (“IDT”), a privately-held manufacturer of custom DNA and RNA oligonucleotides serving customers in the academic and biopharmaceutical research, biotechnology, agriculture, clinical diagnostics and pharmaceutical development end-markets, for an all-cash purchase price of approximately $2.0 billion, including debt assumed and net of cash acquired. IDT had revenues of approximately $260 million in 2017, and is now part of the Company’s Life Sciences segment. The Company financed the acquisition of IDT with available cash and proceeds from the issuance of commercial paper. The acquisition of IDT provides additional sales and earnings growth opportunities for the Company’s Life Sciences segment by expanding the segment’s product line diversity, including new product and service offerings in the area of genomics consumables, and through the potential future acquisition of complementary businesses.

Pro Forma Financial Information

The unaudited pro forma information for the periods set forth below gives effect to the 2017 acquisitions as if they had occurred as of January 1, 2017. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts):



	Three-Month Period Ended
	March 31, 2017
Sales	$	4,245.8
Net earnings from continuing operations	483.3
Diluted net earnings per share from continuing operations	0.69

Discontinued Operations	3 Months Ended
Discontinued Operations	Mar. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	DISCONTINUED OPERATIONS On July 2, 2016 (the “Distribution Date”), the Company completed the separation (the “Separation”) of Fortive Corporation (“Fortive”). For additional details on the Separation reference is made to the financial statements as of and for the year ended December 31, 2017 and Note 3 thereto included in the Company’s 2017 Annual Report. The accounting requirements for reporting the Separation of Fortive as a discontinued operation were met when the Separation was completed. Accordingly, the accompanying consolidated condensed financial statements for all periods presented reflect this business as a discontinued operation. In the three-month period ended March 31, 2017, the Company recorded a $22 million income tax benefit related to the release of previously provided reserves associated with uncertain tax positions on certain Danaher tax returns which were jointly filed with Fortive entities. These reserves were released due to the expiration of statutes of limitations for those returns. This income tax benefit was included in earnings from discontinued operations in the accompanying Consolidated Condensed Statement of Earnings.

Goodwill

3 Months Ended

Mar. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

GOODWILL

The following is a rollforward of the Company’s goodwill ($ in millions):



Balance, December 31, 2017	$	25,138.6
Adjustments due to finalization of purchase price allocations	5.6
Foreign currency translation and other	293.7
Balance, March 30, 2018	$	25,437.9

The carrying value of goodwill by segment is summarized as follows ($ in millions):



	March 30, 2018		December 31, 2017
Life Sciences	$	12,531.2	$	12,335.5
Diagnostics	7,120.3		7,079.5
Dental	3,413.4		3,370.0
Environmental & Applied Solutions	2,373.0		2,353.6
Total	$	25,437.9	$	25,138.6

The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three-month period ended March 30, 2018.

Fair Value Measurements

3 Months Ended

Mar. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
March 30, 2018:
Assets:
Available-for-sale debt securities	$	—	$	43.2	$	—	$	43.2
Liabilities:
Deferred compensation plans	—		59.5		—		59.5

December 31, 2017:
Assets:
Available-for-sale debt securities	$	—	$	45.4	$	—	$	45.4
Liabilities:
Deferred compensation plans	—		62.9		—		62.9

Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Condensed Balance Sheets, are measured at quoted prices reported by investment brokers and dealers based on the underlying terms of the security and comparison to similar securities traded on an active market.

The Company has established nonqualified deferred compensation programs that permit officers, directors and certain management employees to defer a portion of their compensation, on a pretax basis, until at or after their termination of employment (or board service, as applicable). All amounts deferred under such plans are unfunded, unsecured obligations of the Company and are presented as a component of the Company’s compensation and benefits accrual included in other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Participants may choose among alternative earning rates for the amounts they defer, which are primarily based on investment options within the Company’s 401(k) program (except that the earnings rates for amounts deferred by the Company’s directors and amounts contributed unilaterally by the Company are entirely based on changes in the value of the Company’s common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates.

Fair Value of Financial Instruments

The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions):



	March 30, 2018				December 31, 2017
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:
Available-for-sale debt securities	$	43.2	$	43.2	$	45.4	$	45.4
Liabilities:
Notes payable and current portion of long-term debt	98.7		98.7		194.7		194.7
Long-term debt	10,410.7		10,832.0		10,327.4		10,847.1

As of March 30, 2018 and December 31, 2017, available-for-sale debt securities were categorized as Level 2, as indicated above, and short and long-term borrowings were categorized as Level 1.

The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings (other than the Company’s Liquid Yield Option Notes due 2021 (the “LYONs”)) is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. In the case of the LYONs, differences in the fair value from the carrying value are attributable to changes in the price of the Company’s common stock due to the LYONs’ conversion features. The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable approximate their carrying amounts due to the short-term maturities of these instruments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Financing

3 Months Ended

Mar. 30, 2018

Debt Disclosure [Abstract]

Financing

FINANCING

As of March 30, 2018, the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions):



	March 30, 2018		December 31, 2017
U.S. dollar-denominated commercial paper	$	—	$	436.9
Euro-denominated commercial paper (€1.9 billion and €1.7 billion, respectively)	2,345.2		1,993.9
1.65% senior unsecured notes due 2018 (the “2018 U.S. Notes”)	499.5		499.2
1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”)	737.7		718.4
2.4% senior unsecured notes due 2020	497.9		497.7
5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”)	394.5		394.6
Zero-coupon Liquid Yield Option Notes (LYONs) due 2021	60.7		69.1
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	281.7		265.5
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	981.2		955.6
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	307.1		299.1
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	568.0		555.5
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	981.0		955.6
3.35% senior unsecured notes due 2025	496.4		496.3
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	288.8		272.2
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	733.2		714.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	225.0		220.3
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	498.8		470.2
4.375% senior unsecured notes due 2045	499.3		499.3
Other	113.4		208.6
Total debt	10,509.4		10,522.1
Less: currently payable	98.7		194.7
Long-term debt	$	10,410.7	$	10,327.4

For additional details regarding the Company’s debt financing, reference is made to Note 9 of the Company’s financial statements as of and for the year ended December 31, 2017 included in the Company’s 2017 Annual Report.

The Company satisfies any short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. Credit support for the commercial paper programs is generally provided by the Company’s $4.0 billion unsecured, multi-year revolving credit facility with a syndicate of banks that expires on July 10, 2020 (the “Credit Facility”), which can also be used for working capital and other general corporate purposes, and the 364-Day Facility described below. As of March 30, 2018, no borrowings were outstanding under the Credit Facility or the 364-Day Facility, and the Company was in compliance with all covenants thereunder. In addition to the Credit Facility and the 364-Day Facility, the Company has also entered into reimbursement agreements with various commercial banks to support the issuance of letters of credit.

As of March 30, 2018, borrowings outstanding under the Company’s U.S. dollar and euro-denominated commercial paper programs had a weighted average annual interest rate of negative 0.3% and a weighted average remaining maturity of approximately 54 days.

The Company has classified the $500 million of 2018 U.S. Notes and approximately $2.3 billion of its borrowings outstanding under the commercial paper programs as of March 30, 2018 as long-term debt in the accompanying Consolidated Condensed Balance Sheet as the Company had the intent and ability, as supported by availability under the Credit Facility, to refinance these borrowings for at least one year from the balance sheet date.

Debt discounts, premiums and debt issuance costs totaled $23 million and $25 million as of March 30, 2018 and December 31, 2017, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above.

364-Day Revolving Credit Facility

On March 23, 2018, the Company entered into a new $1.0 billion 364-day revolving credit facility (the “364-Day Facility”) to provide liquidity support for the issuance of additional commercial paper to fund a portion of the IDT acquisition (refer to Note 3 for information about the acquisition). The 364-Day Facility expires on March 22, 2019 (the “Scheduled Termination Date”). The Company may elect, upon the payment of a fee equal to 0.75% of the principal amount of the loans then outstanding and, upon the satisfaction of certain conditions, to convert any loans outstanding on the Scheduled Termination Date into term loans that are due and payable one year following the Scheduled Termination Date.

Borrowings under the 364-Day Facility bear interest as follows: (1) Eurodollar Rate Loans bear interest at a variable rate per annum equal to the London inter-bank offered rate plus 81.5 basis points; and (2) Base Rate Loans bear interest at a variable rate per annum equal to the highest of (a) the Federal funds rate (as published by the Federal Reserve Bank of New York from time to time) plus 0.50%, (b) the rate of interest in effect for such day as publicly announced by Bank of America, N.A. as its “prime rate,” and (c) the Eurodollar Rate plus 1.0%. In addition, the Company is required to pay a per annum facility fee of six basis points based on the aggregate commitments under the 364-Day Facility, regardless of usage.

The 364-Day Facility requires the Company to maintain a consolidated leverage ratio of 0.65 to 1.00 or less. Borrowings under the 364-Day Facility are prepayable at the Company’s option at any time in whole or in part without premium or penalty.

The Company’s obligations under the 364-Day Facility are unsecured. The Company has unconditionally and irrevocably guaranteed the obligations of each of its subsidiaries in the event a subsidiary is named a borrower under the 364-Day Facility. The 364-Day Facility contains customary representations, warranties, conditions precedent, events of default, indemnities and affirmative and negative covenants.

Guarantors of Debt

The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned subsidiaries. The 2019, 2022, Floating Rate 2022, 2025 and 2027 Euronotes were issued by DH Europe Finance S.A. (“Danaher International”). The 2023 and 2028 CHF Bonds were issued by DH Switzerland Finance S.A. (“Danaher Switzerland”). The 2021, 2027 and 2032 Yen Notes were issued by DH Japan Finance S.A. (“Danaher Japan”). Each of Danaher International, Danaher Switzerland and Danaher Japan are wholly-owned finance subsidiaries of Danaher Corporation. All of the securities issued by each of these entities, as well as the 2020 Assumed Pall Notes, are fully and unconditionally guaranteed by the Company and these guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness.

LYONs Redemption

During the three-month period ended March 30, 2018, holders of certain of the Company’s LYONs converted such LYONs into an aggregate of approximately 360 thousand shares of the Company’s common stock, par value $0.01 per share. The Company’s deferred tax liability associated with the book and tax basis difference in the converted LYONs of $3 million was transferred to additional paid-in capital as a result of the conversions.

Defined Benefit Plans

3 Months Ended

Mar. 30, 2018

Retirement Benefits [Abstract]

Defined Benefit Plans

DEFINED BENEFIT PLANS

The following sets forth the components of the Company’s net periodic benefit cost of the noncontributory defined benefit pension plans ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
U.S. Pension Benefits:
Service cost	$	(2.1	)	$	(1.9	)
Interest cost	(20.2		)	(21.0		)
Expected return on plan assets	33.1			32.9
Amortization of actuarial loss	(7.8		)	(6.6		)
Amortization of prior service credit	(0.3		)	—
Net periodic pension cost	$	2.7		$	3.4

Non-U.S. Pension Benefits:
Service cost	$	(8.7	)	$	(7.7	)
Interest cost	(6.7		)	(6.3		)
Expected return on plan assets	12.1			10.2
Amortization of actuarial loss	(1.5		)	(1.9		)
Amortization of prior service credit	0.1			0.1
Settlement loss recognized	(0.4		)	—
Net periodic pension cost	$	(5.1	)	$	(5.6	)

The following sets forth the components of the Company’s net periodic benefit cost of the other postretirement employee benefit plans ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Service cost	$	(0.1	)	$	(0.2	)
Interest cost	(1.2		)	(1.3		)
Amortization of prior service credit	0.6			0.8
Net periodic benefit cost	$	(0.7	)	$	(0.7	)

In the first quarter of 2018, the Company adopted ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which requires the Company to disaggregate the service cost component from other components of net periodic benefit costs and report the service cost component in the same line item as other compensation costs and the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. As this ASU requires application on a retrospective basis, the Company restated the prior period presentation for the adoption of this ASU, resulting in a decrease in operating profit and an increase in other income, net of $6.9 million for the three-month period March 31, 2017. The net periodic benefit cost of the noncontributory defined benefit pension plans and other postretirement employee benefit plans incurred during the three-month periods ended March 30, 2018 and March 31, 2017 are reflected in the following captions in the accompanying Consolidated Condensed Statement of Earnings ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Service cost:
Cost of sales	$	(2.1	)	$	(2.0	)
Selling, general and administrative expenses	(8.8		)	(7.8		)
Total service cost	(10.9		)	(9.8		)
Other net periodic benefit costs:
Other income, net	7.8			6.9
Total	$	(3.1	)	$	(2.9	)

Employer Contributions

During 2018, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are forecasted to be approximately $30 million and $55 million, respectively. The ultimate amounts to be contributed depend upon, among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of the contribution, local practices, market conditions, interest rates and other factors.

Income Taxes

3 Months Ended

Mar. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The Company’s effective tax rate from continuing operations for the three-month period ended March 30, 2018 was 20.5%, as compared to 17.3% for the three-month period ended March 31, 2017.

The Company’s effective tax rate for 2018 was slightly lower than the U.S. federal statutory rate of 21.0% due principally to the impact of the Company’s earnings outside the United States which generally are taxed at rates lower than the U.S. federal rate. The 2018 effective tax rate includes the benefit of a lower U.S. corporate income tax rate of 21.0% from the enactment of TCJA, partially offset by a new minimum tax on certain non-U.S. earnings. The effective tax rate for the three-month period ended March 30, 2018 also includes tax benefits for release of reserves upon the expiration of statutes of limitation and excess tax benefits from stock-based compensation which were offset by changes in estimates associated with prior period uncertain tax provisions and other matters.

The Company’s effective tax rate for 2017 differs from the U.S. federal statutory rate of 35.0% due principally to the Company’s earnings outside the United States which generally are taxed at rates lower than the U.S. federal rate. In addition, the excess tax benefits from stock-based compensation and the release of reserves upon the expiration of statutes of limitation, partially offset by recording valuation allowances on certain foreign operating losses decreased the reported tax rate for the three-month period ended March 31, 2017 by 3.2%.

On December 22, 2017, the TCJA was enacted, substantially changing the U.S. tax system and affecting the Company in a number of ways. Notably, the TCJA:


•	establishes a flat corporate income tax rate of 21.0% on U.S. earnings;


•	imposes a one-time tax on unremitted cumulative non-U.S. earnings of foreign subsidiaries (“Transition Tax”);


•	imposes a new minimum tax on certain non-U.S. earnings, irrespective of the territorial system of taxation, and generally allows for the repatriation of future earnings of foreign subsidiaries without incurring additional U.S. taxes by transitioning to a territorial system of taxation (Global Intangible Low-Taxed Income or “GILTI Tax”);


•	subjects certain payments made by a U.S. company to a related foreign company to certain minimum taxes (Base Erosion Anti-Abuse Tax);


•	eliminates certain prior tax incentives for manufacturing in the United States and creates an incentive for U.S. companies to sell, lease or license goods and services abroad by allowing for a reduction in taxes owed on earnings related to such sales;


•	allows the cost of investments in certain depreciable assets acquired and placed in service after September 27, 2017 to be immediately expensed; and


•	reduces deductions with respect to certain compensation paid to specified executive officers.

As U.S. GAAP accounting for income taxes requires the effect of a change in tax laws or rates to be recognized in income from continuing operations for the period that includes the enactment date, the Company recognized an estimate of the impact of the TCJA in the year ended December 31, 2017. As a result of the TCJA, the Company recognized a provisional tax liability of approximately $1.2 billion in 2017 for the Transition Tax, which is payable over a period of eight years. The Company also remeasured U.S. deferred tax assets and liabilities based on the income tax rates at which the deferred tax assets and liabilities are expected to reverse in the future (generally 21.0%), resulting in an income tax benefit of approximately $1.2 billion in 2017. For a description of the impact of the TCJA for the year ended December 31, 2017 reference is made to Note 12 of the Company’s financial statements as of and for the year ended December 31, 2017 included in the Company’s 2017 Annual Report.

Due to the complexities involved in accounting for the enactment of the TCJA, SAB No. 118 allowed the Company to record provisional amounts in earnings for the year ended December 31, 2017. SAB No. 118 provides that where reasonable estimates can be made, the provisional accounting should be based on such estimates and when no reasonable estimate can be made, the provisional accounting may be based on the tax law in effect before the TCJA. During the three-month period ended March 30, 2018, there were no changes made to the provisional amounts recognized in 2017. The Company will continue to analyze the effects of the TCJA on its Consolidated Condensed Financial Statements. Additional impacts from the enactment of the TCJA will be recorded as they are identified during the measurement period as provided for in SAB No. 118, which extends up to one year from the enactment date. The final impact of the TCJA may differ from the provisional amounts that have been recognized, possibly materially, due to, among other things, changes in the Company’s interpretation of the TCJA, legislative or administrative actions to clarify the intent of the statutory language provided that differ from the Company’s current interpretation, any changes in accounting standards for income taxes or related interpretations in response to the TCJA, or any updates or changes to estimates utilized to calculate the impacts, including changes to current year earnings estimates and applicable foreign exchange rates. Additionally, the Company’s U.S. tax returns for 2017 will be filed during the fourth quarter of 2018 and any changes to the tax positions for temporary differences compared to the estimates used will result in an adjustment of the estimated tax benefit recorded as of December 31, 2017.

The Company also continues to evaluate the impact of the GILTI provisions under the TCJA which are complex and subject to continuing regulatory interpretation by the U.S. Internal Revenue Service (“IRS”). The Company is required to make an accounting policy election of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or (2) factoring such amounts into the Company’s measurement of its deferred taxes (the “deferred method”). The Company’s accounting policy election with respect to the new GILTI Tax rules will depend, in part, on analyzing its global income to determine whether it can reasonably estimate the tax impact. While the Company has included an estimate of GILTI in its estimated effective tax rate for 2018, it has not completed its analysis and is not yet able to determine which method to elect. Adjustments related to the amount of GILTI Tax recorded in its consolidated financial statements may be required based on the outcome of this election.

Tax authorities in Denmark have raised significant issues related to interest accrued by certain of the Company’s subsidiaries. On December 10, 2013, the Company received assessments from the Danish tax authority (“SKAT”) totaling approximately DKK 1.5 billion including interest through March 30, 2018 (approximately $254 million based on the exchange rate as of March 30, 2018), imposing withholding tax relating to interest accrued in Denmark on borrowings from certain of the Company’s subsidiaries for the years 2004-2009. The Company is currently in discussions with SKAT and anticipates receiving an assessment for years 2010-2012 totaling approximately DKK 909 million including interest through March 30, 2018 (approximately $150 million based on the exchange rate as of March 30, 2018). Management believes the positions the Company has taken in Denmark are in accordance with the relevant tax laws and is vigorously defending its positions. The Company appealed these assessments to the National Tax Tribunal in 2014 and intends on pursuing this matter through the European Court of Justice should this appeal be unsuccessful. The ultimate resolution of this matter is uncertain, could take many years, and could result in a material adverse impact to the Company’s financial statements, including its effective tax rate.

Nonoperating Income (Expense)	3 Months Ended
Nonoperating Income (Expense)	Mar. 30, 2018
Other Income and Expenses [Abstract]
Nonoperating Income (Expense)	NONOPERATING INCOME (EXPENSE) As described in Note 1 and Note 8, in the first quarter of 2018, the Company adopted ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The ASU requires the Company to disaggregate the service cost component from the other components of net periodic benefit costs and requires application on a retrospective basis. As such, the other components of net periodic benefit costs included in other income, net for the three-month periods ended March 30, 2018 and March 31, 2017 were $7.8 million and $6.9 million, respectively.

Commitments And Contingencies

3 Months Ended

Mar. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES

For a description of the Company’s litigation and contingencies, reference is made to Note 16 of the Company’s financial statements as of and for the year ended December 31, 2017 included in the Company’s 2017 Annual Report.

The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known.

The following is a rollforward of the Company’s accrued warranty liability ($ in millions):



Balance, December 31, 2017	$	79.0
Accruals for warranties issued during the period	14.1
Settlements made	(16.3		)
Effect of foreign currency translation	0.9
Balance, March 30, 2018	$	77.7

Stock Transactions And Stock-Based Compensation

3 Months Ended

Mar. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Transactions And Stock-Based Compensation

STOCK TRANSACTIONS AND STOCK-BASED COMPENSATION

Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the three-month period ended March 30, 2018. On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. As of March 30, 2018, 20 million shares remained available for repurchase pursuant to the Repurchase Program.

For a full description of the Company’s stock-based compensation programs, reference is made to Note 17 of the Company’s financial statements as of and for the year ended December 31, 2017 included in the Company’s 2017 Annual Report. As of March 30, 2018, approximately 61 million shares of the Company’s common stock were reserved for issuance under the 2007 Omnibus Incentive Plan.

The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Restricted stock units (“RSUs”)/performance stock units (“PSUs”):
Pretax compensation expense	$	20.9		$	21.6
Income tax benefit	(4.4		)	(6.7		)
RSU/PSU expense, net of income taxes	16.5			14.9
Stock options:
Pretax compensation expense	12.4			12.0
Income tax benefit	(2.6		)	(3.8		)
Stock option expense, net of income taxes	9.8			8.2
Total stock-based compensation:
Pretax compensation expense	33.3			33.6
Income tax benefit	(7.0		)	(10.5		)
Total stock-based compensation expense, net of income taxes	$	26.3		$	23.1

Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. As of March 30, 2018, $213 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately three years. As of March 30, 2018, $177 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately three years. Future compensation amounts will be adjusted for any changes in estimated forfeitures.

Net Earnings Per Share From Continuing Operations

3 Months Ended

Mar. 30, 2018

Earnings Per Share [Abstract]

Net Earnings Per Share From Continuing Operations

NET EARNINGS PER SHARE FROM CONTINUING OPERATIONS

Basic net earnings per share (“EPS”) from continuing operations is calculated by dividing net earnings from continuing operations by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS from continuing operations is computed based on the weighted average number of common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three-month periods ended March 30, 2018 and March 31, 2017, approximately three million and four million options to purchase shares, respectively, were not included in the diluted EPS from continuing operations calculation as the impact of their inclusion would have been anti-dilutive.

Information related to the calculation of net earnings per share from continuing operations is summarized as follows ($ and shares in millions, except per share amounts):



	Net Earnings from Continuing Operations (Numerator)		Shares (Denominator)	Per Share Amount
For the Three-Month Period Ended March 30, 2018:
Basic EPS	$	566.6	698.6	$	0.81
Adjustment for interest on convertible debentures	0.6		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		8.3
Incremental shares from assumed conversion of the convertible debentures	—		2.6
Diluted EPS	$	567.2	709.5	$	0.80

For the Three-Month Period Ended March 31, 2017:
Basic EPS	$	483.8	694.3	$	0.70
Adjustment for interest on convertible debentures	0.5		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		8.5
Incremental shares from assumed conversion of the convertible debentures	—		2.9
Diluted EPS	$	484.3	705.7	$	0.69

Segment Information

3 Months Ended

Mar. 30, 2018

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

The Company operates and reports its results in four separate business segments consisting of the Life Sciences, Diagnostics, Dental and Environmental & Applied Solutions segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. There has been no material change in total assets or liabilities by segment since December 31, 2017.

Segment results are shown below ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Sales:
Life Sciences	$	1,476.0		$	1,308.1
Diagnostics	1,519.7			1,327.3
Dental	672.6			655.5
Environmental & Applied Solutions	1,027.1			914.8
Total	$	4,695.4		$	4,205.7

Operating profit:
Life Sciences	$	271.3		$	211.6
Diagnostics	248.0			154.6
Dental	50.9			89.4
Environmental & Applied Solutions	227.2			208.0
Other	(54.4		)	(46.6		)
Total	$	743.0		$	617.0

General (Policies)	3 Months Ended
General (Policies)	Mar. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Standards	Accounting Standards Recently Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) which supersedes nearly all existing revenue recognition guidance. Subsequent to the issuance of Topic 606, the FASB clarified the guidance through several Accounting Standard Updates; hereinafter the collection of revenue guidance is referred to as “ASC 606”. The core principle of ASC 606 is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. On January 1, 2018, the Company adopted ASC 606 using the modified retrospective method for all contracts. Results for reporting periods beginning January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with the Company’s historic accounting under Topic 605, Revenue Recognition. The Company recorded a net increase to beginning retained earnings of $3 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606. The impact to beginning retained earnings was primarily driven by the capitalization of certain costs to obtain a contract, primarily sales-related commissions, partially offset by the deferral of revenue for unfulfilled performance obligations. The adoption of ASC 606 did not have a significant impact on the Company’s Consolidated Condensed Financial Statements as of and for the three-month period ended March 30, 2018 and, as a result, comparisons of revenues and operating profit performance between periods are not affected by the adoption of this ASU. Refer to Note 2 for additional disclosures required by ASC 606. The Company derives revenues primarily from the sale of Life Sciences, Diagnostics, Dental and Environmental & Applied Solutions products and services. Revenue is recognized when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606. For equipment, consumables, spare parts and most software licenses sold by the Company, control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment, legal title must have passed to the customer, the customer must have the significant risks and rewards of ownership, and where acceptance is not a formality, the customer must have accepted the product or service. The Company’s principal terms of sale are FOB Shipping Point, or equivalent, and, as such, the Company primarily transfers control and records revenue for product sales upon shipment. Sales arrangements with delivery terms that are not FOB Shipping Point are not recognized upon shipment and the transfer of control for revenue recognition is evaluated based on the associated shipping terms and customer obligations. If a performance obligation to the customer with respect to a sales transaction remains to be fulfilled following shipment (typically installation or acceptance by the customer), revenue recognition for that performance obligation is deferred until such commitments have been fulfilled. Returns for products sold are estimated and recorded as a reduction of revenue at the time of sale. Customer allowances and rebates, consisting primarily of volume discounts and other short-term incentive programs, are recorded as a reduction of revenue at the time of sale because these allowances reflect a reduction in the transaction price. Product returns, customer allowances and rebates are estimated based on historical experience and known trends. For extended warranty, service, post contract support (“PCS”), software-as-a-service (“SaaS”) and other long-term contracts, control transfers to the customer over the term of the arrangement. Revenue for extended warranty, service, PCS, SaaS and certain software licenses is recognized based upon the period of time elapsed under the arrangement. Revenue for other long-term contracts is generally recognized based upon the cost-to-cost measure of progress, provided that the Company meets the criteria associated with transferring control of the good or service over time. Certain of the Company’s revenues relate to operating-type lease (“OTL”) arrangements. Leases are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Instrument lease revenue for OTL agreements is recognized on a straight-line basis over the life of the lease, and the costs of customer-leased instruments are recorded within property, plant and equipment in the accompanying Consolidated Balance Sheets and depreciated over the instrument’s estimated useful life. The depreciation expense is reflected in cost of sales in the accompanying Consolidated Statements of Earnings. The OTLs are generally not cancellable until after an initial term and may or may not require the customer to purchase a minimum number of consumables or tests throughout the contract term. Certain of the Company’s lease contracts are customized for larger customers and often result in complex terms and conditions that typically require significant judgment in applying the criteria used to evaluate whether the arrangement should be considered an OTL or a sales-type lease (“STL”). A sales-type lease would result in earlier recognition of instrument revenue as compared to an OTL. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis using the Company’s best estimate of the standalone selling price of each distinct product or service in the contract. The primary method used to estimate standalone selling price is the price observed in standalone sales to customers, however when prices in standalone sales are not available the Company may use third-party pricing for similar products or services or estimate the standalone selling price. Allocation of the transaction price is determined at the contracts’ inception. The Company does not adjust transaction price for the effects of a significant financing component when the period between the transfer of the promised good or service to the customer and payment for that good or service by the customer is expected to be one year or less. This allocation approach also applies to contracts for which a portion of the contract relates to a lease component. In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. The ASU amends guidance on the classification and measurement of financial instruments, including significant revisions in accounting related to the classification and measurement of investments in equity securities and presentation of certain fair value changes for financial liabilities when the fair value option is elected. The ASU requires equity securities to be measured at fair value with changes in fair value recognized through net earnings and amends certain disclosure requirements associated with the fair value of financial instruments. In the period of adoption, the Company is required to reclassify the unrealized gains/losses on equity securities within accumulated other comprehensive income (loss) to retained earnings. In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10), which clarified certain aspects of the previously issued ASU. The ASU was adopted by the Company on January 1, 2018 and did not have a material effect on the Company’s Consolidated Financial Statements. In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which requires employers to disaggregate the service cost component from other components of net periodic benefit costs and to disclose the amounts of net periodic benefit costs that are included in each income statement line item. The standard requires employers to report the service cost component in the same line item as other compensation costs and to report the other components of net periodic benefit costs (which include interest costs, expected return on plan assets, amortization of prior service cost or credits and actuarial gains and losses) separately and outside a subtotal of operating income. The income statement guidance requires application on a retrospective basis. The ASU was adopted by the Company on January 1, 2018 and as a result operating profit decreased and other income, net increased by $6.9 million for the three-month period March 31, 2017. Refer to Note 8 for further information on the implementation of this ASU. The Company measures its pension and postretirement plans’ assets and its obligations that determine the respective plan’s funded status as of the end of the Company’s fiscal year, and recognizes an asset for a plan’s overfunded status or a liability for a plan’s underfunded status in its balance sheet. Changes in the funded status of the plans are recognized in the year in which the changes occur and reported in other comprehensive income (loss). The service cost component of net periodic pension cost is included in cost of sales and selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings and the other components of net periodic pension cost are included in nonoperating income (expense). In February 2018, the FASB issued ASU No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, to address a specific consequence of the Tax Cuts and Jobs Act (“TCJA”) by allowing a reclassification from accumulated other comprehensive income (loss) to retained earnings for stranded tax effects resulting from the TCJA’s reduction of the U.S. federal corporate income tax rate. The standard is effective for all entities for annual periods beginning after December 15, 2018, with early adoption permitted, and is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company early adopted this ASU on January 1, 2018 and as a result recorded a net increase to beginning retained earnings and decrease to accumulated other comprehensive income (loss) of $151 million to reclassify the income tax effects of the TCJA on the Company’s U.S. pension plans, available-for-sale debt securities and certain foreign currency losses. The ASU also requires the Company to disclose its policy on accounting for income tax effects in accumulated other comprehensive income (loss). In general, the Company applies the individual item approach with respect to available-for-sale debt securities and the portfolio approach with respect to pension, postretirement benefit plan obligations and currency translation matters. In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the TCJA. The Company recognized the estimated income tax effects of the TCJA in its 2017 Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin No. 118 (“SAB No. 118”). Refer to Note 9 for further information regarding the provisional amounts recorded by the Company as of December 31, 2017. Except for the above accounting policy for revenue recognition that was updated as a result of adopting ASC 606 and the policy for pension and postretirement benefit plans that was updated as a result of adopting ASU 2017-07, there have been no changes to the Company’s significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2017 that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes. Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. Currently, the Company believes that the most notable impact of this ASU will relate to its processes around the assessment of the adequacy of its allowance for doubtful accounts on trade accounts receivable and the recognition of credit losses. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize a right-of-use asset and a lease liability for all leases with terms greater than 12 months. The standard also requires disclosures by lessees and lessors about the amount, timing and uncertainty of cash flows arising from leases. The accounting applied by a lessor is largely unchanged from that applied under the current standard. The standard must be adopted using a modified retrospective transition approach and provides for certain practical expedients. The ASU is effective for public entities for fiscal years beginning after December 15, 2018, with early adoption permitted. In September 2017 and January 2018, the FASB issued ASU No. 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), and ASU No. 2018-01, Leases (Topic 842), Land Easement Practical Expedient for Transition to Topic 842, which provided additional implementation guidance on the previously issued ASU. Management has not yet completed its assessment of the impact of the new standard on the Company’s Consolidated Financial Statements. The Company is in the early stages of implementation and currently believes that the most notable impact to its financial statements upon the adoption of this ASU will be the recognition of a material right-of-use asset and a lease liability for its real estate and equipment leases.

General (Tables)

3 Months Ended

Mar. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Components Of Accumulated Other Comprehensive Income (Loss)



	Foreign Currency Translation Adjustments			Pension & Postretirement Plan Benefit Adjustments				Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments			Total
For the Three-Month Period Ended March 30, 2018:
Balance, December 31, 2017	$	(1,422.1	)	$	(571.2	)		$	(0.9	)	$	(1,994.2	)
Adoption of accounting standards	(43.8		)	(107.2		)		(0.2		)	(151.2		)
Balance, January 1, 2018	(1,465.9		)	(678.4		)		(1.1		)	(2,145.4		)
Other comprehensive income (loss) before reclassifications:
Increase (decrease)	294.1			—				(0.8		)	293.3
Income tax impact	—			—				0.3			0.3
Other comprehensive income (loss) before reclassifications, net of income taxes	294.1			—				(0.5		)	293.6
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			9.3			(a)	—			9.3
Income tax impact	—			(2.2		)		—			(2.2		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			7.1				—			7.1
Net current period other comprehensive income (loss), net of income taxes	294.1			7.1				(0.5		)	300.7
Balance, March 30, 2018	$	(1,171.8	)	$	(671.3	)		$	(1.6	)	$	(1,844.7	)
For the Three-Month Period Ended March 31, 2017:
Balance, December 31, 2016	$	(2,398.2	)	$	(642.2	)		$	18.7		$	(3,021.7	)
Other comprehensive income (loss) before reclassifications:
Increase	304.3			—				11.7			316.0
Income tax impact	—			—				(4.4		)	(4.4		)
Other comprehensive income (loss) before reclassifications, net of income taxes	304.3			—				7.3			311.6
Amounts reclassified from accumulated other comprehensive income (loss):
Increase	—			7.6			(a)	—			7.6
Income tax impact	—			(2.7		)		—			(2.7		)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	—			4.9				—			4.9
Net current period other comprehensive income (loss), net of income taxes	304.3			4.9				7.3			316.5
Balance, March 31, 2017	$	(2,093.9	)	$	(637.3	)		$	26.0		$	(2,705.2	)

^(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost. Refer to Note 8 for additional details.

Revenue (Tables)

3 Months Ended

Mar. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue



	Life Sciences		Diagnostics		Dental		Environmental & Applied Solutions		Total
Geographical region:
North America	$	480.4	$	607.4	$	291.3	$	418.3	$	1,797.4
Western Europe	449.9		310.4		175.6		264.8		1,200.7
Other developed markets	144.9		92.2		43.9		31.6		312.6
High-growth markets	400.8		509.7		161.8		312.4		1,384.7
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

Revenue type:
Recurring	$	970.4	$	1,308.5	$	488.0	$	557.0	$	3,323.9
Nonrecurring	505.6		211.2		184.6		470.1		1,371.5
Total	$	1,476.0	$	1,519.7	$	672.6	$	1,027.1	$	4,695.4

Acquisitions (Tables)

3 Months Ended

Mar. 30, 2018

Business Combinations [Abstract]

Results Of Operations If Acquisition Was Consummated

The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts):



	Three-Month Period Ended
	March 31, 2017
Sales	$	4,245.8
Net earnings from continuing operations	483.3
Diluted net earnings per share from continuing operations	0.69

Goodwill (Tables)

3 Months Ended

Mar. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Rollforward Of Goodwill

The following is a rollforward of the Company’s goodwill ($ in millions):



Balance, December 31, 2017	$	25,138.6
Adjustments due to finalization of purchase price allocations	5.6
Foreign currency translation and other	293.7
Balance, March 30, 2018	$	25,437.9

The carrying value of goodwill by segment is summarized as follows ($ in millions):



	March 30, 2018		December 31, 2017
Life Sciences	$	12,531.2	$	12,335.5
Diagnostics	7,120.3		7,079.5
Dental	3,413.4		3,370.0
Environmental & Applied Solutions	2,373.0		2,353.6
Total	$	25,437.9	$	25,138.6

Fair Value Measurements (Tables)

3 Months Ended

Mar. 30, 2018

Fair Value Disclosures [Abstract]

Financial Assets And Liabilities Carried At Fair Value

A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions):



	Quoted Prices in Active Market (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
March 30, 2018:
Assets:
Available-for-sale debt securities	$	—	$	43.2	$	—	$	43.2
Liabilities:
Deferred compensation plans	—		59.5		—		59.5

December 31, 2017:
Assets:
Available-for-sale debt securities	$	—	$	45.4	$	—	$	45.4
Liabilities:
Deferred compensation plans	—		62.9		—		62.9

Carrying Amounts And Fair Values Of Financial Instruments

The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions):



	March 30, 2018				December 31, 2017
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Assets:
Available-for-sale debt securities	$	43.2	$	43.2	$	45.4	$	45.4
Liabilities:
Notes payable and current portion of long-term debt	98.7		98.7		194.7		194.7
Long-term debt	10,410.7		10,832.0		10,327.4		10,847.1

Financing (Tables)

3 Months Ended

Mar. 30, 2018

Debt Disclosure [Abstract]

Components Of Debt

The components of the Company’s debt were as follows ($ in millions):



	March 30, 2018		December 31, 2017
U.S. dollar-denominated commercial paper	$	—	$	436.9
Euro-denominated commercial paper (€1.9 billion and €1.7 billion, respectively)	2,345.2		1,993.9
1.65% senior unsecured notes due 2018 (the “2018 U.S. Notes”)	499.5		499.2
1.0% senior unsecured notes due 2019 (€600.0 million aggregate principal amount) (the “2019 Euronotes”)	737.7		718.4
2.4% senior unsecured notes due 2020	497.9		497.7
5.0% senior unsecured notes due 2020 (the “2020 Assumed Pall Notes”)	394.5		394.6
Zero-coupon Liquid Yield Option Notes (LYONs) due 2021	60.7		69.1
0.352% senior unsecured notes due 2021 (¥30.0 billion aggregate principal amount) (the “2021 Yen Notes”)	281.7		265.5
1.7% senior unsecured notes due 2022 (€800.0 million aggregate principal amount) (the “2022 Euronotes”)	981.2		955.6
Floating rate senior unsecured notes due 2022 (€250.0 million aggregate principal amount) (the “Floating Rate 2022 Euronotes”)	307.1		299.1
0.5% senior unsecured bonds due 2023 (CHF 540.0 million aggregate principal amount) (the “2023 CHF Bonds”)	568.0		555.5
2.5% senior unsecured notes due 2025 (€800.0 million aggregate principal amount) (the “2025 Euronotes”)	981.0		955.6
3.35% senior unsecured notes due 2025	496.4		496.3
0.3% senior unsecured notes due 2027 (¥30.8 billion aggregate principal amount) (the “2027 Yen Notes”)	288.8		272.2
1.2% senior unsecured notes due 2027 (€600.0 million aggregate principal amount) (the “2027 Euronotes”)	733.2		714.1
1.125% senior unsecured bonds due 2028 (CHF 210.0 million aggregate principal amount) (the “2028 CHF Bonds”)	225.0		220.3
0.65% senior unsecured notes due 2032 (¥53.2 billion aggregate principal amount) (the “2032 Yen Notes”)	498.8		470.2
4.375% senior unsecured notes due 2045	499.3		499.3
Other	113.4		208.6
Total debt	10,509.4		10,522.1
Less: currently payable	98.7		194.7
Long-term debt	$	10,410.7	$	10,327.4

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Defined Benefit Plans (Tables)

3 Months Ended

Mar. 30, 2018

Defined Benefit Plan Disclosure [Line Items]

Schedule of Defined Benefit Plans Disclosures

The net periodic benefit cost of the noncontributory defined benefit pension plans and other postretirement employee benefit plans incurred during the three-month periods ended March 30, 2018 and March 31, 2017 are reflected in the following captions in the accompanying Consolidated Condensed Statement of Earnings ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Service cost:
Cost of sales	$	(2.1	)	$	(2.0	)
Selling, general and administrative expenses	(8.8		)	(7.8		)
Total service cost	(10.9		)	(9.8		)
Other net periodic benefit costs:
Other income, net	7.8			6.9
Total	$	(3.1	)	$	(2.9	)

Defined benefit pension plans

Defined Benefit Plan Disclosure [Line Items]

Schedule of Net Benefit Costs

The following sets forth the components of the Company’s net periodic benefit cost of the noncontributory defined benefit pension plans ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
U.S. Pension Benefits:
Service cost	$	(2.1	)	$	(1.9	)
Interest cost	(20.2		)	(21.0		)
Expected return on plan assets	33.1			32.9
Amortization of actuarial loss	(7.8		)	(6.6		)
Amortization of prior service credit	(0.3		)	—
Net periodic pension cost	$	2.7		$	3.4

Non-U.S. Pension Benefits:
Service cost	$	(8.7	)	$	(7.7	)
Interest cost	(6.7		)	(6.3		)
Expected return on plan assets	12.1			10.2
Amortization of actuarial loss	(1.5		)	(1.9		)
Amortization of prior service credit	0.1			0.1
Settlement loss recognized	(0.4		)	—
Net periodic pension cost	$	(5.1	)	$	(5.6	)

Other postretirement benefit plans

Defined Benefit Plan Disclosure [Line Items]

Schedule of Net Benefit Costs

The following sets forth the components of the Company’s net periodic benefit cost of the other postretirement employee benefit plans ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Service cost	$	(0.1	)	$	(0.2	)
Interest cost	(1.2		)	(1.3		)
Amortization of prior service credit	0.6			0.8
Net periodic benefit cost	$	(0.7	)	$	(0.7	)

Commitments And Contingencies (Tables)

3 Months Ended

Mar. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Warranty Accrual

The following is a rollforward of the Company’s accrued warranty liability ($ in millions):



Balance, December 31, 2017	$	79.0
Accruals for warranties issued during the period	14.1
Settlements made	(16.3		)
Effect of foreign currency translation	0.9
Balance, March 30, 2018	$	77.7

Stock Transactions And Stock-Based Compensation (Tables)

3 Months Ended

Mar. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Components Of Stock-Based Compensation Program

The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Restricted stock units (“RSUs”)/performance stock units (“PSUs”):
Pretax compensation expense	$	20.9		$	21.6
Income tax benefit	(4.4		)	(6.7		)
RSU/PSU expense, net of income taxes	16.5			14.9
Stock options:
Pretax compensation expense	12.4			12.0
Income tax benefit	(2.6		)	(3.8		)
Stock option expense, net of income taxes	9.8			8.2
Total stock-based compensation:
Pretax compensation expense	33.3			33.6
Income tax benefit	(7.0		)	(10.5		)
Total stock-based compensation expense, net of income taxes	$	26.3		$	23.1

Net Earnings Per Share From Continuing Operations (Tables)

3 Months Ended

Mar. 30, 2018

Earnings Per Share [Abstract]

Components Of Basic And Diluted Earnings Per Share

Information related to the calculation of net earnings per share from continuing operations is summarized as follows ($ and shares in millions, except per share amounts):



	Net Earnings from Continuing Operations (Numerator)		Shares (Denominator)	Per Share Amount
For the Three-Month Period Ended March 30, 2018:
Basic EPS	$	566.6	698.6	$	0.81
Adjustment for interest on convertible debentures	0.6		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		8.3
Incremental shares from assumed conversion of the convertible debentures	—		2.6
Diluted EPS	$	567.2	709.5	$	0.80

For the Three-Month Period Ended March 31, 2017:
Basic EPS	$	483.8	694.3	$	0.70
Adjustment for interest on convertible debentures	0.5		—
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs	—		8.5
Incremental shares from assumed conversion of the convertible debentures	—		2.9
Diluted EPS	$	484.3	705.7	$	0.69

Segment Information (Tables)

3 Months Ended

Mar. 30, 2018

Segment Reporting [Abstract]

Segment Results

Segment results are shown below ($ in millions):



	Three-Month Period Ended
	March 30, 2018			March 31, 2017
Sales:
Life Sciences	$	1,476.0		$	1,308.1
Diagnostics	1,519.7			1,327.3
Dental	672.6			655.5
Environmental & Applied Solutions	1,027.1			914.8
Total	$	4,695.4		$	4,205.7

Operating profit:
Life Sciences	$	271.3		$	211.6
Diagnostics	248.0			154.6
Dental	50.9			89.4
Environmental & Applied Solutions	227.2			208.0
Other	(54.4		)	(46.6		)
Total	$	743.0		$	617.0

General (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended
General (Narrative) (Details) - USD ($) $ in Millions	Jan. 01, 2018	Mar. 31, 2017
Accumulated Other Comprehensive Income (Loss)
Cumulative effect of new accounting principle in period of adoption	$ (151.2)
ASU 2014-09
New accounting pronouncement or change in accounting principle, effect of change on beginning retained earnings	3.0
ASU 2017-07
New accounting pronouncement or change in accounting principle, effect of change on operating results		$ 6.9
New accounting pronouncement or change in accounting principle, effect of change on other income		$ 6.9
ASU 2018-02
New accounting pronouncement or change in accounting principle, effect of change on beginning retained earnings	$ 151.0

General (Components of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions		3 Months Ended
	Jan. 01, 2018	Mar. 30, 2018	Mar. 31, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	$ (1,994.2)	$ (1,994.2)
Total other comprehensive income (loss), net of income taxes		300.7	$ 316.5
Ending balance		(1,844.7)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(1,422.1)	(1,422.1)	(2,398.2)
Adoption of accounting standards	(43.8)
Increase (decrease)		294.1	304.3
Income tax impact		0.0	0.0
Other comprehensive income (loss) before reclassifications, net of income taxes		294.1	304.3
Increase (decrease)		0.0	0.0
Income tax impact		0.0	0.0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		0.0	0.0
Total other comprehensive income (loss), net of income taxes		294.1	304.3
Ending balance	(1,465.9)	(1,171.8)	(2,093.9)
Pension & Postretirement Plan Benefit Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(571.2)	(571.2)	(642.2)
Adoption of accounting standards	(107.2)
Increase (decrease)		0.0	0.0
Income tax impact		0.0	0.0
Other comprehensive income (loss) before reclassifications, net of income taxes		0.0	0.0
Increase (decrease)		9.3	7.6
Income tax impact		(2.2)	(2.7)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		7.1	4.9
Total other comprehensive income (loss), net of income taxes		7.1	4.9
Ending balance	(678.4)	(671.3)	(637.3)
Unrealized Gain (Loss) on Available-For-Sale Securities Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(0.9)	(0.9)	18.7
Adoption of accounting standards	(0.2)
Increase (decrease)		(0.8)	11.7
Income tax impact		0.3	(4.4)
Other comprehensive income (loss) before reclassifications, net of income taxes		(0.5)	7.3
Increase (decrease)		0.0	0.0
Income tax impact		0.0	0.0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		0.0	0.0
Total other comprehensive income (loss), net of income taxes		(0.5)	7.3
Ending balance	(1.1)	(1.6)	26.0
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(1,994.2)	(1,994.2)	(3,021.7)
Adoption of accounting standards	(151.2)
Increase (decrease)		293.3	316.0
Income tax impact		0.3	(4.4)
Other comprehensive income (loss) before reclassifications, net of income taxes		293.6	311.6
Increase (decrease)		9.3	7.6
Income tax impact		(2.2)	(2.7)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes		7.1	4.9
Total other comprehensive income (loss), net of income taxes		300.7	316.5
Ending balance	$ (2,145.4)	$ (1,844.7)	$ (2,705.2)

Revenue (Disaggregation of Revenue by Geographical Region) (Details) $ in Millions	3 Months Ended
	Mar. 30, 2018 USD ($)
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 4,695.4
North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,797.4
Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,200.7
Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	312.6
High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,384.7
Life Sciences
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,476.0
Life Sciences \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	480.4
Life Sciences \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	449.9
Life Sciences \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	144.9
Life Sciences \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	400.8
Diagnostics
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,519.7
Diagnostics \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	607.4
Diagnostics \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	310.4
Diagnostics \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	92.2
Diagnostics \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	509.7
Dental
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	672.6
Dental \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	291.3
Dental \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	175.6
Dental \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	43.9
Dental \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	161.8
Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,027.1
Environmental & Applied Solutions \| North America
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	418.3
Environmental & Applied Solutions \| Western Europe
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	264.8
Environmental & Applied Solutions \| Other developed markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	31.6
Environmental & Applied Solutions \| High-growth markets
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 312.4

Revenue (Disaggregation of Revenue by Revenue Type) (Details) $ in Millions	3 Months Ended
	Mar. 30, 2018 USD ($)
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 4,695.4
Life Sciences
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,476.0
Diagnostics
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,519.7
Dental
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	672.6
Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,027.1
Recurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	3,323.9
Recurring \| Life Sciences
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	970.4
Recurring \| Diagnostics
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,308.5
Recurring \| Dental
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	488.0
Recurring \| Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	557.0
Nonrecurring
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	1,371.5
Nonrecurring \| Life Sciences
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	505.6
Nonrecurring \| Diagnostics
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	211.2
Nonrecurring \| Dental
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	184.6
Nonrecurring \| Environmental & Applied Solutions
Disaggregation of Revenue [Line Items]
Revenue from contract with customer, excluding assessed tax	$ 470.1

Revenue (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended
Revenue (Narrative) (Details) - USD ($) $ in Millions	Mar. 30, 2018	Mar. 30, 2018	Jan. 01, 2018
Revenue from Contract with Customer [Abstract]
Operation-type lease and sales-type lease, revenues		$ 97
Revenue, remaining performance obligation	$ 1,700	1,700
Revenue, remaining performance obligation, expected satisfaction in th next two years, percent	72.00%
Revenue, remaining performance obligation, expected satisfaction in the next 12 months, percent	44.00%
Revenue, remaining performance obligation, expected satisfaction in year two, percent	28.00%
Contract with customer, asset, net	$ 94	94	$ 114
Contract with customer, liability	$ 801	801	$ 783
Contract with customer, liability, revenue recognized		$ 265

Acquisitions (Narrative) (Details) - IDT - Operating segments - Life Sciences - Subsequent event $ in Millions	1 Months Ended
	Apr. 18, 2018 USD ($)
Business Acquisition [Line Items]
Business combination, consideration transferred	$ 2,000
Revenue reported by acquired entity for last annual period	$ 260

Acquisitions (Results of Operations if Acquisitions Consummated) (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($) $ / shares
Business Combinations [Abstract]
Sales	$ 4,245.8
Net earnings from continuing operations	$ 483.3
Diluted net earnings per share from continuing operations \| $ / shares	$ 0.69

Discontinued Operations (Narrative) (Details) $ in Millions	3 Months Ended
Discontinued Operations (Narrative) (Details) $ in Millions	Mar. 31, 2017 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Income tax benefit	$ 22

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

Goodwill (Rollforward of Goodwill) (Details) $ in Millions	3 Months Ended
Goodwill (Rollforward of Goodwill) (Details) $ in Millions	Mar. 30, 2018 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 25,138.6
Adjustments due to finalization of purchase price allocations	5.6
Foreign currency translation and other	293.7
Ending balance	$ 25,437.9

Goodwill (Goodwill by Segment) (Details) - USD ($) $ in Millions	Mar. 30, 2018	Dec. 31, 2017
Goodwill [Line Items]
Total goodwill	$ 25,437.9	$ 25,138.6
Operating segments \| Life Sciences
Goodwill [Line Items]
Total goodwill	12,531.2	12,335.5
Operating segments \| Diagnostics
Goodwill [Line Items]
Total goodwill	7,120.3	7,079.5
Operating segments \| Dental
Goodwill [Line Items]
Total goodwill	3,413.4	3,370.0
Operating segments \| Environmental & Applied Solutions
Goodwill [Line Items]
Total goodwill	$ 2,373.0	$ 2,353.6

Fair Value Measurements (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Mar. 30, 2018	Dec. 31, 2017
Assets:
Available-for-sale securities	$ 43.2	$ 45.4
Liabilities:
Deferred compensation plans	59.5	62.9
Quoted Prices in Active Market (Level 1)
Assets:
Available-for-sale securities	0.0	0.0
Liabilities:
Deferred compensation plans	0.0	0.0
Significant Other Observable Inputs (Level 2)
Assets:
Available-for-sale securities	43.2	45.4
Liabilities:
Deferred compensation plans	59.5	62.9
Significant Unobservable Inputs (Level 3)
Assets:
Available-for-sale securities	0.0	0.0
Liabilities:
Deferred compensation plans	$ 0.0	$ 0.0

Fair Value Measurements (Carrying Amounts and Fair Values of Financial Instruments) (Details) - USD ($) $ in Millions	Mar. 30, 2018	Dec. 31, 2017
Assets:
Available-for-sale securities, carrying amount	$ 43.2	$ 45.4
Available-for-sale securities, fair value	43.2	45.4
Liabilities:
Notes payable and current portion of long-term debt	98.7	194.7
Long-term debt	10,410.7	10,327.4
Notes payable and current portion of long-term debt, fair value	98.7	194.7
Long-term debt, fair value	$ 10,832.0	$ 10,847.1

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References + Details

Financing (Components Of Debt) (Details) € in Millions, SFr in Millions, $ in Millions, ¥ in Billions	Mar. 30, 2018 CHF (SFr)	Mar. 30, 2018 JPY (¥)	Mar. 30, 2018 USD ($)	Mar. 30, 2018 EUR (€)	Dec. 31, 2017 CHF (SFr)	Dec. 31, 2017 JPY (¥)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)
Debt Instrument [Line Items]
Long-term debt			$ 10,509.4				$ 10,522.1
Less: currently payable			98.7				194.7
Long-term debt excluding currently payable			10,410.7				10,327.4
Other
Debt Instrument [Line Items]
Long-term debt			113.4				208.6
Commercial paper
Debt Instrument [Line Items]
Long-term debt			2,300.0
Commercial paper \| U.S. dollar-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt			0.0				436.9
Commercial paper \| Euro-denominated commercial paper
Debt Instrument [Line Items]
Long-term debt			2,345.2	€ 1,900.0			1,993.9	€ 1,700.0
Senior notes \| 1.65% senior unsecured notes due 2018
Debt Instrument [Line Items]
Long-term debt			$ 499.5				499.2
Interest rate of debt instrument	1.65%	1.65%	1.65%	1.65%
Debt instrument, face value			$ 500.0
Senior notes \| 1.0% senior unsecured notes due 2019
Debt Instrument [Line Items]
Long-term debt			$ 737.7				718.4
Interest rate of debt instrument	1.00%	1.00%	1.00%	1.00%
Debt instrument, face value \| €				€ 600.0				600.0
Senior notes \| 2.4% senior unsecured notes due 2020
Debt Instrument [Line Items]
Long-term debt			$ 497.9				497.7
Interest rate of debt instrument	2.40%	2.40%	2.40%	2.40%
Senior notes \| 5.0% senior notes due 2020
Debt Instrument [Line Items]
Long-term debt			$ 394.5				394.6
Interest rate of debt instrument	5.00%	5.00%	5.00%	5.00%
Senior notes \| 0.352% senior unsecured notes due 2021
Debt Instrument [Line Items]
Long-term debt			$ 281.7				265.5
Interest rate of debt instrument	0.352%	0.352%	0.352%	0.352%
Debt instrument, face value \| ¥		¥ 30.0				¥ 30.0
Senior notes \| 1.7% senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt			$ 981.2				955.6
Interest rate of debt instrument	1.70%	1.70%	1.70%	1.70%
Debt instrument, face value \| €				€ 800.0				800.0
Senior notes \| Floating rate senior unsecured notes due 2022
Debt Instrument [Line Items]
Long-term debt			$ 307.1				299.1
Debt instrument, face value \| €				€ 250.0				250.0
Senior notes \| 2.5% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt			$ 981.0				955.6
Interest rate of debt instrument	2.50%	2.50%	2.50%	2.50%
Debt instrument, face value \| €				€ 800.0				800.0
Senior notes \| 3.35% senior unsecured notes due 2025
Debt Instrument [Line Items]
Long-term debt			$ 496.4				496.3
Interest rate of debt instrument	3.35%	3.35%	3.35%	3.35%
Senior notes \| 0.3% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt			$ 288.8				272.2
Interest rate of debt instrument	0.30%	0.30%	0.30%	0.30%
Debt instrument, face value \| ¥		¥ 30.8				30.8
Senior notes \| 1.2% senior unsecured notes due 2027
Debt Instrument [Line Items]
Long-term debt			$ 733.2				714.1
Interest rate of debt instrument	1.20%	1.20%	1.20%	1.20%
Debt instrument, face value \| €				€ 600.0				€ 600.0
Senior notes \| 0.65% senior unsecured notes due 2032
Debt Instrument [Line Items]
Long-term debt			$ 498.8				470.2
Interest rate of debt instrument	0.65%	0.65%	0.65%	0.65%
Debt instrument, face value \| ¥		¥ 53.2				¥ 53.2
Senior notes \| 4.375% senior unsecured notes due 2045
Debt Instrument [Line Items]
Long-term debt			$ 499.3				499.3
Interest rate of debt instrument	4.375%	4.375%	4.375%	4.375%
Bonds \| 0.5% senior unsecured bonds due 2023
Debt Instrument [Line Items]
Long-term debt			$ 568.0				555.5
Interest rate of debt instrument	0.50%	0.50%	0.50%	0.50%
Debt instrument, face value \| SFr	SFr 540.0				SFr 540.0
Bonds \| 1.125% senior unsecured bonds due 2028
Debt Instrument [Line Items]
Long-term debt			$ 225.0				220.3
Interest rate of debt instrument	1.125%	1.125%	1.125%	1.125%
Debt instrument, face value \| SFr	SFr 210.0				SFr 210.0
Convertible debt \| Zero-coupon LYONs due 2021
Debt Instrument [Line Items]
Long-term debt			$ 60.7				$ 69.1
Interest rate of debt instrument	0.00%	0.00%	0.00%	0.00%

Financing (Narrative) (Details) $ / shares in Units, shares in Thousands			3 Months Ended
	Mar. 30, 2018 USD ($) $ / shares	Mar. 23, 2018 USD ($)	Mar. 30, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares
Debt Instrument [Line Items]
Long-term debt	$ 10,509,400,000		$ 10,509,400,000	$ 10,522,100,000
Debt discounts, premiums and debt issuance costs	$ 23,000,000		$ 23,000,000	$ 25,000,000
Common stock, par value \| $ / shares	$ 0.01		$ 0.01	$ 0.01
Debt conversion, converted instrument, tax benefit			$ 3,100,000
Long-term debt \| Revolving credit facility \| Credit facility
Debt Instrument [Line Items]
Line of credit	$ 4,000,000,000		4,000,000,000
Line of credit facility, amount outstanding	0		0
Short-term debt \| Revolving credit facility \| 364-day facility
Debt Instrument [Line Items]
Line of credit		$ 1,000,000,000
Line of credit facility, amount outstanding	$ 0		$ 0
Debt instrument, fee to convert to term loan, percent		0.75%
Line of credit facility, commitment fee percent		0.06%
Short-term debt \| Revolving credit facility \| 364-day facility \| Maximum
Debt Instrument [Line Items]
Ratio of indebtedness to net capital		0.65
LIBOR \| Short-term debt \| Revolving credit facility \| 364-day facility
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.815%
Federal funds \| Short-term debt \| Revolving credit facility \| 364-day facility
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.50%
Eurodollar \| Short-term debt \| Revolving credit facility \| 364-day facility
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.00%
Commercial paper
Debt Instrument [Line Items]
Weighted average interest rate of long-term debt, interest rate	(0.30%)		(0.30%)
Weighted average maturity of long-term debt, term	54 days
Long-term debt	$ 2,300,000,000		$ 2,300,000,000
Senior notes \| 1.65% senior unsecured notes due 2018
Debt Instrument [Line Items]
Debt instrument, face value	500,000,000		500,000,000
Long-term debt	499,500,000		499,500,000	$ 499,200,000
Convertible debt \| Zero-coupon LYONs due 2021
Debt Instrument [Line Items]
Long-term debt	$ 60,700,000		$ 60,700,000	$ 69,100,000
Shares issued under debt conversion, shares \| shares			360
Debt conversion, converted instrument, tax benefit			$ 3,000,000

Defined Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Mar. 30, 2018
Defined benefit pension plans \| U.S.
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions, current fiscal year		$ 30.0
Defined benefit pension plans \| Non-U.S.
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions, current fiscal year		$ 55.0
ASU 2017-07
Defined Benefit Plan Disclosure [Line Items]
New accounting pronouncement or change in accounting principle, effect of change on operating results	$ (6.9)
New accounting pronouncement or change in accounting principle, effect of change on other income	$ 6.9

Defined Benefit Plans (Components of Net Periodic Benefit Cost of Defined Benefit Pension Pans) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (10.9)	$ (9.8)
Net periodic benefit cost	(3.1)	(2.9)
Defined benefit pension plans \| U.S.
Defined Benefit Plan Disclosure [Line Items]
Service cost	(2.1)	(1.9)
Interest cost	(20.2)	(21.0)
Expected return on plan assets	(33.1)	(32.9)
Amortization of actuarial loss	7.8	6.6
Amortization of prior service credit	(0.3)	0.0
Net periodic benefit cost	2.7	3.4
Defined benefit pension plans \| Non-U.S.
Defined Benefit Plan Disclosure [Line Items]
Service cost	(8.7)	(7.7)
Interest cost	(6.7)	(6.3)
Expected return on plan assets	(12.1)	(10.2)
Amortization of actuarial loss	1.5	1.9
Amortization of prior service credit	0.1	0.1
Settlement loss recognized	(0.4)	0.0
Net periodic benefit cost	$ (5.1)	$ (5.6)

Defined Benefit Plans (Components of Net Periodic Benefit Cost of Other Postretirement Benefit Pension Pans) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (10.9)	$ (9.8)
Net periodic benefit cost	(3.1)	(2.9)
Other postretirement benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	(0.1)	(0.2)
Interest cost	(1.2)	(1.3)
Amortization of prior service credit	(0.6)	(0.8)
Net periodic benefit cost	$ (0.7)	$ (0.7)

Defined Benefit Plans (Components of Net Periodic Benefit Cost Reflected in the Consolidated Condensed Statement of Earnings) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Total service cost	$ (10.9)	$ (9.8)
Other income, net	7.8	6.9
Net periodic benefit cost	(3.1)	(2.9)
Cost of sales
Defined Benefit Plan Disclosure [Line Items]
Total service cost	(2.1)	(2.0)
Selling, general and administrative expenses
Defined Benefit Plan Disclosure [Line Items]
Total service cost	$ (8.8)	$ (7.8)

Income Taxes (Narrative) (Details) kr in Millions, $ in Millions			3 Months Ended		12 Months Ended	36 Months Ended
	Mar. 30, 2018 USD ($)	Dec. 22, 2017	Mar. 30, 2018 USD ($)	Mar. 31, 2017	Dec. 31, 2017 USD ($)	Dec. 31, 2012 DKK (kr)	Dec. 10, 2013 DKK (kr)
Income Tax Examination [Line Items]
Effective income tax rate, percent			20.50%	17.30%
Federal statutory income tax rate, percent		21.00%	21.00%		35.00%
Effective income tax rate reconciliation, other reconciling items, percent				(3.20%)
TCJA, transition tax, provisional tax liability					$ 1,200
TCJA, transition tax, provisional tax liability, term					8 years
TCJA, income tax benefit					$ 1,200
Foreign tax authority
Income Tax Examination [Line Items]
Income tax examination, amount of tax assessments	$ 254		$ 254				kr 1,500
Income tax examination, amount of potential additional tax assessments	$ 150					kr 909

Nonoperating Income (Expense) (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Other Income and Expenses [Abstract]
Other income, net	$ 7.8	$ 6.9

Commitments And Contingencies (Narrative) (Details)	3 Months Ended
Commitments And Contingencies (Narrative) (Details)	Mar. 30, 2018
Minimum
Warranty period, term	90 days

Commitments And Contingencies (Warranty Accrual) (Details) $ in Millions	3 Months Ended
	Mar. 30, 2018 USD ($)
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
December 31, 2017	$ 79.0
Accruals for warranties issued during the period	14.1
Settlements made	(16.3)
Effect of foreign currency translation	0.9
March 30, 2018	$ 77.7

Stock Transactions And Stock-Based Compensation (Narrative) (Details) - USD ($) shares in Millions, $ in Millions	Mar. 30, 2018	Jul. 16, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized shares to be repurchased, shares		20
Stock repurchase program, remaining number of shares authorized to be repurchased, shares	20
Common shares reserved for issuance under the 2007 Omnibus Incentive Plan, shares	61
Restricted stock units (“RSUs”)/performance stock units (“PSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 213
Weighted average period for cost to be recognized	3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 177
Weighted average period for cost to be recognized	3 years

Stock Transactions And Stock-Based Compensation (Components of Stock-Based Compensation Program) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	$ 33.3	$ 33.6
Income tax benefit	(7.0)	(10.5)
Stock-based compensation expense, net of income taxes	26.3	23.1
Restricted stock units (“RSUs”)/performance stock units (“PSUs”)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	20.9	21.6
Income tax benefit	(4.4)	(6.7)
Stock-based compensation expense, net of income taxes	16.5	14.9
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pretax compensation expense	12.4	12.0
Income tax benefit	(2.6)	(3.8)
Stock-based compensation expense, net of income taxes	$ 9.8	$ 8.2

Net Earnings Per Share From Continuing Operations (Narrative) (Details) - shares shares in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, shares	3	4

Net Earnings Per Share From Continuing Operations (Components of Basic and Diluted Earnings per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Basis EPS, net earnings from continuing operations (numerator)	$ 566.6	$ 483.8
Adjustment for interest on convertible debentures, net earnings from continuing operations (numerator)	0.6	0.5
Diluted EPS, net earnings from continuing operations (numerator)	$ 567.2	$ 484.3
Basic EPS, shares (denominator)	698.6	694.3
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs, shares (denominator)	8.3	8.5
Incremental shares from assumed conversion of the convertible debentures, shares (denominator)	2.6	2.9
Diluted EPS, shares (denominator)	709.5	705.7
Basis EPS, per share amount	$ 0.81	$ 0.70
Diluted EPS, per share amount	$ 0.80	$ 0.69

Segment Information (Segment Results) (Details) $ in Millions	3 Months Ended
	Mar. 30, 2018 USD ($) Business_Segments	Mar. 31, 2017 USD ($)
Segment Reporting Information [Line Items]
Number of segments reported \| Business_Segments	4
Sales	$ 4,695.4	$ 4,205.7
Operating profit	743.0	617.0
Other
Segment Reporting Information [Line Items]
Operating profit	(54.4)	(46.6)
Life Sciences \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,476.0	1,308.1
Operating profit	271.3	211.6
Diagnostics \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,519.7	1,327.3
Operating profit	248.0	154.6
Dental \| Operating segments
Segment Reporting Information [Line Items]
Sales	672.6	655.5
Operating profit	50.9	89.4
Environmental & Applied Solutions \| Operating segments
Segment Reporting Information [Line Items]
Sales	1,027.1	914.8
Operating profit	$ 227.2	$ 208.0